[
  {
    "ts": null,
    "headline": "Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy.",
    "summary": "Pharmaceutical stocks breathed a sigh of relief Friday after the Trump administration agreed to a 15% tariffs on drug imports from Europe.",
    "url": "https://finnhub.io/api/news?id=f76d09ba029e17bd343e0632632abb518c72515fb7c30e42960e7f31682d25ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755893646,
      "headline": "Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy.",
      "id": 136496013,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pharmaceutical stocks breathed a sigh of relief Friday after the Trump administration agreed to a 15% tariffs on drug imports from Europe.",
      "url": "https://finnhub.io/api/news?id=f76d09ba029e17bd343e0632632abb518c72515fb7c30e42960e7f31682d25ab"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth",
    "summary": "ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.",
    "url": "https://finnhub.io/api/news?id=70f3dd6c2b69b2c91a5bf2faf1f22e846bf3388610f0401f0532df8a98bdeb6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755869940,
      "headline": "AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth",
      "id": 136478895,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.",
      "url": "https://finnhub.io/api/news?id=70f3dd6c2b69b2c91a5bf2faf1f22e846bf3388610f0401f0532df8a98bdeb6d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?",
    "summary": "There are some reasons to be worried; there are also reasons to be optimistic.",
    "url": "https://finnhub.io/api/news?id=975016834132423d3ef5bcb1b4ecabc5276b64a648337e2ff7fa85e359ff6609",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755869400,
      "headline": "Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?",
      "id": 136476598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "There are some reasons to be worried; there are also reasons to be optimistic.",
      "url": "https://finnhub.io/api/news?id=975016834132423d3ef5bcb1b4ecabc5276b64a648337e2ff7fa85e359ff6609"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=5f5ae92e88bdb6eff0adc0b33c8801c2cea93a2c70db335db2809e89a787d5d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755867604,
      "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 136476599,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=5f5ae92e88bdb6eff0adc0b33c8801c2cea93a2c70db335db2809e89a787d5d5"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to participate in Wells Fargo 20th Annual Healthcare Conference",
    "summary": "Eli Lilly and Company (NYSE:LLY) will participate in the Wells Fargo 20th Annual Healthcare Conference on Sept. 5, 2025. Patrik Jonsson, executive vice president and president of Lilly International, will take part in a fireside chat at 9:30 a.m., Eastern time.",
    "url": "https://finnhub.io/api/news?id=20aa5543447a09679aa31de2811c7175e123578f06df38bd38f056715b8b21fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755867600,
      "headline": "Lilly to participate in Wells Fargo 20th Annual Healthcare Conference",
      "id": 136476600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) will participate in the Wells Fargo 20th Annual Healthcare Conference on Sept. 5, 2025. Patrik Jonsson, executive vice president and president of Lilly International, will take part in a fireside chat at 9:30 a.m., Eastern time.",
      "url": "https://finnhub.io/api/news?id=20aa5543447a09679aa31de2811c7175e123578f06df38bd38f056715b8b21fb"
    }
  },
  {
    "ts": null,
    "headline": "Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?",
    "summary": "Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes alive.",
    "url": "https://finnhub.io/api/news?id=4c3610180fc907fd1be9af7a8152268c3fbfb51964572e397772d49a05007260",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755866940,
      "headline": "Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?",
      "id": 136476601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes alive.",
      "url": "https://finnhub.io/api/news?id=4c3610180fc907fd1be9af7a8152268c3fbfb51964572e397772d49a05007260"
    }
  },
  {
    "ts": null,
    "headline": "Investors Crave Long-Term Debt, But Firms Don’t Want to Sell",
    "summary": "When blue-chip companies have sold debt maturing in 30 years or more in the US, they’ve found heavy demand, with money managers placing orders equal to about five times the notes for sale on average.  Drugmaker Eli Lilly & Co drew $14.7 billion of orders earlier this week for just $2 billion of 30- and 40-year bonds.  Investors are eager to lock in yields above 5.5%, a relatively high level, especially as money managers enjoy robust inflows and the Federal Reserve gets closer to cutting rates.",
    "url": "https://finnhub.io/api/news?id=5a68ebd2e1f002224dadbac608b50cb7f6df768e90c4de79fe70887b6e682f67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755864009,
      "headline": "Investors Crave Long-Term Debt, But Firms Don’t Want to Sell",
      "id": 136476603,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "When blue-chip companies have sold debt maturing in 30 years or more in the US, they’ve found heavy demand, with money managers placing orders equal to about five times the notes for sale on average.  Drugmaker Eli Lilly & Co drew $14.7 billion of orders earlier this week for just $2 billion of 30- and 40-year bonds.  Investors are eager to lock in yields above 5.5%, a relatively high level, especially as money managers enjoy robust inflows and the Federal Reserve gets closer to cutting rates.",
      "url": "https://finnhub.io/api/news?id=5a68ebd2e1f002224dadbac608b50cb7f6df768e90c4de79fe70887b6e682f67"
    }
  },
  {
    "ts": null,
    "headline": "Wegovy sales spike after maker of rival Mounjaro ramps up UK price",
    "summary": "CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication.",
    "url": "https://finnhub.io/api/news?id=6e17a322ae4fd343bceedb3bb51260509a7e8d53072500ee7c11c4f32952f32d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755856118,
      "headline": "Wegovy sales spike after maker of rival Mounjaro ramps up UK price",
      "id": 136476604,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication.",
      "url": "https://finnhub.io/api/news?id=6e17a322ae4fd343bceedb3bb51260509a7e8d53072500ee7c11c4f32952f32d"
    }
  },
  {
    "ts": null,
    "headline": "EU-USA Trade Framework Should Instill Market Optimism",
    "summary": "The US-EU trade dealâs softer stance lifts sentiment, aiding EU autos and pharma, but uncertainty remains. See why holding is best amid Fed and market risks.",
    "url": "https://finnhub.io/api/news?id=ed441b704d57aad48bc15b4226b5ecacf56fa14386a462453241944c9b2cc33e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755854100,
      "headline": "EU-USA Trade Framework Should Instill Market Optimism",
      "id": 136476123,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2197808065/image_2197808065.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The US-EU trade dealâs softer stance lifts sentiment, aiding EU autos and pharma, but uncertainty remains. See why holding is best amid Fed and market risks.",
      "url": "https://finnhub.io/api/news?id=ed441b704d57aad48bc15b4226b5ecacf56fa14386a462453241944c9b2cc33e"
    }
  }
]